Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma
Status:
Completed
Trial end date:
2018-08-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the combination of X4P-001 plus nivolumab is
safe and tolerable. Secondly, the study will investigate if adding X4P-001 to nivolumab
treatment has an effect on the body and the cancer tumor, in participants receiving nivolumab
but not exhibiting a radiological response.